Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (1y) (2013 - 2025)
Nu-Med Plus (NUMD) Net Income towards Common Stockholders Growth (1y) (2013 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 98.96% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 89.28% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -30.10% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 121.14% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | -19.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -19.55% |
| Sep 30, 2025 | 35.93% |
| Jun 30, 2025 | 32.52% |
| Mar 31, 2025 | 8.67% |
| Dec 31, 2024 | 81.35% |
| Sep 30, 2024 | -13.84% |
| Jun 30, 2024 | 28.92% |
| Mar 31, 2024 | 22.61% |
| Dec 31, 2023 | -232.84% |
| Sep 30, 2023 | 71.74% |
| Jun 30, 2023 | 58.12% |
| Mar 31, 2023 | 52.72% |
| Dec 31, 2022 | 101.95% |
| Sep 30, 2022 | 50.96% |
| Jun 30, 2022 | 76.06% |
| Mar 31, 2022 | 83.28% |
| Dec 31, 2021 | -330.45% |
| Sep 30, 2021 | 73.92% |
| Jun 30, 2021 | 73.30% |
| Mar 31, 2021 | -132.66% |